Transplantation of umbilical cord blood (CB) from related or unrelated donors is carried out as a means of increasing the number of potential allogeneic stem cell donors. 1 The clinical experience from more than 2000 cord blood transplants (CBT) has shown that CB represents a successful alternative source of haematopoietic stem cells for allografting patients with malignant or nonmalignant disorders. 2, 3 Over the last decade, advances in the understanding of transplant immunobiology and the clinical potential of CBT have been achieved by intensive scientific research and clinical data analysis, respectively. Little research, however, has been carried out comparing the genotypic properties of the CB cells transplanted and the clinical outcomes after transplant. This is mainly due to the very limited amount of material available for research from the CB donations. Clinical CB transplants often require the maximum CB donation to reach the minimum cell dose for successful engraftment. It is almost impossible to store any samples from CB donations (cells or DNA) for the purpose of retrospective or prospective studies. Despite the great success in CBT, a large number of research questions remains to be answered regarding the roles, for example, of high-resolution tissue typing, genetic polymorphisms of minor histocompatibility antigens, non-classical MHC molecules, NK cell receptors, cytokine gene polymorphisms and cytokine receptors in determining CBT outcome. Furthermore, certain unknown genetic factors or polymorphisms associated with the control of allorecognition or innate immunity may be discovered in future studies. The effect of these factors on CBT outcome could be an important area of further research. We therefore propose to establish Epstein-Barr virus (EBV)-transformed cell lines from CBT recipient/donor pairs. The resulting cell lines will provide an unlimited source of DNA for future studies. Informed consent for the use of the CB samples for research was obtained prior to the study.
The standard protocol for B-cell EBV transformation using adult peripheral blood mononuclear cells is not suitable for CB samples due to the cell numbers required for the transformation. The difference in EBV immune status between adult and CB cells may also affect the efficacy of EBV transformation using CB. In order to establish the minimal cell dose required for a successful EBV transformation and to increase the efficiency of CB cell EBV transformation, different protocols were tested and modified. The protocol of the Newcastle group used CB mononuclear cells or cells remaining in the processing bags after collecting the cells for transplantation. The culture medium was RPMI supplemented with 2 mM L-glutamine, antibiotics and 10% FCS. A titrated number of CB mononuclear cells (1 Â 10 4 -1 Â 10 6 ) were mixed with B95-8 viral suspensions in a Universal tube (Sterilin, UK) at a volume ratio of 1:1 and a total volume of 600 ml. After 2 h incubation at 371C, cyclosporin A (CSA, 1 mg/ ml) was added and incubated overnight. The cultures were then transferred to 24-well tissue culture plate, replenished with 1 ml fresh medium containing CSA (1 mg/ml) and cultured for 2 weeks with weekly medium change. Cultures beyond 2 weeks were carried out in T25 culture flasks in medium without CSA. A successful transformation of CB cells was initially estimated by the appearance of multiple transformed foci, 4 then confirmed by continued proliferation of these transformed cells, with concurrent formation of large aggregates and the ability of the cells to undergo long-term expansion. The protocol of the Paris group used fresh whole CB (0.5-1 ml) in the absence of CSA. Briefly, following two washes, the pellet, containing 0.5-1 Â 10 6 nucleated cells, was resuspended in 0.5 ml RPMI-20%FCS and mixed with 1 ml B95-8 viral suspension. After 2 h incubation at 371C, 1.5 ml of culture medium was added and the cells were further incubated in T25 tissue culture flasks with weekly medium change.
The results showed that the time between EBV infection and a successful transformation was significantly associated with the initiating numbers of CB cells (Figure 1 , P ¼ 0.001). Although a successful EBV transformation is achievable at cell numbers as low as 0.1 Â 10 5 , the cell number of more than 0.5 Â 10 5 required a much shorter time scale. Co-workers at St Louis Hospital, Paris have also shown that successful EBV transformation can be achieved using a small volume (0.5 ml) of whole CB in the absence of CSA (n ¼ 17). In a small number of samples (n ¼ 3), the effect of RBC lysis was tested using a titrated volume (0.3-0.1 ml) of whole blood. The results showed that the volume of blood required for a successful EBV transformation could be reduced to 0.1 ml and RBC lysis significantly reduced the time between EBV infection and transformation (Po0.01, Table 1a ). In order to make the procedure more applicable and more relevant to the clinical setting, we carried out CB EBV transformation using the residual cells left in the processing bags after the recovery and transplantation of cryopreserved CB donations. The processing bag was washed thoroughly with EBSS. The remaining cells were collected by centrifugation at 400 g for 5 min. A 100% success rate of transformation was achieved using the cells collected from rinsing the used processing bags (n ¼ 12, Table 1b ).
The presence of CSA can promote EBV transformation of mononuclear cells from EBV-seropositive individuals by suppressing the cytotoxic T-cell responses, which inhibit transformation. 5, 6 Successful CB cell EBV transformations could be achieved without the use of CSA due to the lack of memory EBV-specific CD8 þ cytotoxic T-lymphocytes in CB. A comparison between the samples transformed using the protocols with or without CSA performed in Newcastle and Paris, respectively, showed that the transformation efficiency was slightly less in the absence of CSA but the difference did not reach statistical significance (P ¼ 0.17, Table 1b ). In parallel paired experiments (n ¼ 4), comparative results were observed in terms of the successful rate of CB EBV transformation and the total cell yield within a short time scale of 4 weeks (data not shown). However, the presence of CSA may be beneficial in suppressing CB CD4 þ T cells, which could limit the expansion of EBV-infected cells in longer-term expansion cultures. 7, 8 In conclusion, we have shown that it is feasible to generate EBV cell lines from a minimal number of cells and/or a minimal volume of CB. Transplant patient and donor DNA from the resulting immortalized cell lines could then be available for genetic studies focusing on the effect of HLA and non-HLA gene polymorphisms on the outcome of CBT. Although EBV transformation of CB cells can be achieved using various protocols, the remaining cells in the CB processing bag are a good source of material for successful EBV transformation without reducing the number of cells available in the CB donation for clinical transplantation. Initiating cell number(x10 5 ) Time to achieve transformation (weeks) Figure 1 Association between the initiating cell number and the time to achieve a successful EBV transformation. The result shown is the mean time to achieve transformation from five individual experiments. a RBC lysis was achieved by gentle resuspension of the cell pellet in 0.5 ml sterile distilled water for 10-15 s. A measure of 25 ml of 20% FCS-RPMI was added immediately after RBC lysis. The result shown is the mean time to achieve transformation from three individual experiments. b Ly: lymphocyte. c The result shown was obtained using CB mononuclear cells (7/19 ) and the residual cells collected from the used processing bags (12/19). A 100% success rate of transformation was achieved using the cells collected from rinsing the used processing bags (12/12).
